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Splenic marginal zone lymphoma (SMZL) is a B cell malignancy of unknown pathogenesis, 
and thus an orphan of targeted therapies. By integrating whole-exome sequencing and 
copy-number analysis, we show that the SMZL exome carries at least 30 nonsilent gene 
alterations. Mutations in NOTCH2, a gene required for marginal-zone (MZ) B cell develop-
ment, represent the most frequent lesion in SMZL, accounting for ~20% of cases. All 
NOTCH2 mutations are predicted to cause impaired degradation of the NOTCH2 protein by 
eliminating the C-terminal PEST domain, which is required for proteasomal recruitment. 
Among indolent B cell lymphoproliferative disorders, NOTCH2 mutations are restricted to 
SMZL, thus representing a potential diagnostic marker for this lymphoma type. In addition 
to NOTCH2, other modulators or members of the NOTCH pathway are recurrently targeted 
by genetic lesions in SMZL; these include NOTCH1, SPEN, and DTX1. We also noted muta-
tions in other signaling pathways normally involved in MZ B cell development, suggesting 
that deregulation of MZ B cell development pathways plays a role in the pathogenesis of 
~60% SMZL. These findings have direct implications for the treatment of SMZL patients, 
given the availability of drugs that can target NOTCH, NF-kB, and other pathways deregu-
lated in this disease.
© 2012 Rossi et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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sequencing and high-density SNP array analysis of paired tumor 
and normal DNA from eight untreated individuals diagnosed 
with SMZL (Table S1).
After enrichment of protein-coding genes by a hybridization-
capture method, next-generation sequencing was performed 
using the Illumina HiSeq2000 instrument (Table S2). The 
whole-exome sequencing approach allowed us to map an 
average of 102.5 million reads per sample at a mean depth 
of 110.6× (range, 59.0-137.0× per sample), with an average 
of 83.3% of the target sequence being covered by at least 
30 reads (range, 72.0–86.0%; Table S2). Bioinformatic analy-
sis followed by Sanger resequencing validation confirmed the 
presence of 203 somatic, nonsilent mutations (mean, 25.3/
case; range, 12–44/case), affecting 191 distinct genes (valida-
tion rate, 92.6%; Fig. 1, A–D, and Table S3). The relative 
expression of the variant allele was determined by transcrip-
tome analysis, performed in 6 of the 8 cases (Table S3).
By using the Affymetrix SNP6.0 platform, 41 somatic 
CNAs (30 deletions and 11 gains) were identified in the 
8 discovery SMZL cases (mean, 5.1/case; range, 0–19/case; 
Fig. 1 E and Table S4). Alterations known to be associated 
with SMZL (3q gain, 7q31-q32 deletion, 17p deletion) and 
previously detected by FISH were correctly identified using 
the SNP array approach. Of the 41 CNAs, 8 (7 losses and 
1 gain) were defined as focal, i.e., spanning ≤3 genes, with 
none being recurrently observed. When combining point 
mutations and CNAs, the overall load of tumor-acquired 
lesions was heterogeneous across the 8 SMZL cases investi-
gated, ranging from 13–60 lesions/case (mean load, 30.5 
lesions/case; Fig. 1 F).
Genes identified through the whole-exome sequencing 
and high-resolution SNP array approaches were prioritized 
for further assessment of their mutation frequency according 
to the fulfillment of one or more of the following criteria: 
(a) mutation recurrence in the discovery panel; (b) involvement 
by both point mutations and focal copy number changes or 
truncating deletions; and (c) involvement in cellular pathways 
known a priori to be potentially relevant for SMZL biology. 
The analysis was also extended to selected genes that were 
either involved in the same pathways as the genes found to be 
altered in the discovery genomes (n = 7, including NOTCH1, 
FBXW7, SPEN, PTEN, CTNNB1, CD79A, and CD79B) 
and/or those previously implicated in SMZL pathogenesis 
(n = 7, including IKBKB, TNFAIP3, TRAF3, MAP3K14, 
TP53, CARD11, and MYD88; Rossi et al., 2011; Yan et al., 
2012), even if they were not identified in the discovery phase. 
Based on these criteria, 61 genes (47 revealed by the genomic 
approach in the discovery panel, and 14 involved in the same 
pathways as genes mutated in the discovery genome) were 
analyzed by Sanger-based resequencing of their coding exons 
and consensus splice sites in an independent screening panel 
of 32 SMZL cases (Table S5); for selected genes, an additional 
extension panel of 77 SMZL cases was also analyzed (Table S6; 
total number of cases, 109).
Of the 61 genes investigated, 21 were found to be mu-
tated in at least two SMZL cases, and 18 were altered in ≥5% 
Splenic marginal zone (MZ) lymphoma (SMZL) is a neoplasm 
of mature B cells that affects elderly patients and involves the 
spleen, bone marrow, and peripheral blood, while typically 
sparing peripheral lymph nodes and other sites populated by 
MZ B cells, namely mucosa-associated lymphoid tissue sites 
(Matutes et al., 2008; Swerdlow et al., 2008; Traverse-Glehen 
et al., 2011). Within the spleen, tumor cells are represented by 
small lymphocytes that occupy the MZ surrounding germinal 
centers and infiltrate the red pulp (Swerdlow et al., 2008). Despite 
an indolent behavior in the majority of patients, 25% of 
SMZL patients experience a progressive course leading to 
early death (Matutes et al., 2008; Salido et al., 2010).
The pathogenesis of SMZL is currently elusive. Clinical 
and epidemiological data point to an association with hepatitis 
C virus (HCV); however, the infection rate in SMZL patients 
does not exceed 15%, even in geographic areas in which 
the virus is endemic (Hermine et al., 2002; Suarez et al., 2006). 
The contribution of antigen stimulation to SMZL pathogenesis 
is suggested by the highly restricted immunoglobulin gene 
repertoire, including selective usage of the immunoglobulin 
heavy chain variable (IGHV) 1-2*04 allele in 20–30% of 
cases, but the relevant antigen has not been identified (Warsame 
et al., 2011; Bikos et al., 2012).
Although the molecular pathogenesis of many lymphoma 
entities has been elucidated in detail (Swerdlow et al., 2008), 
relatively little is known about the genetic lesions associated 
with SMZL. Deletions of 7q31-q32 and gains of 3q are recur-
rent in 20–30% and 10–20% of cases, respectively, but the 
genes targeted by these lesions are unknown (Salido et al., 2010; 
Watkins et al., 2010; Rinaldi et al., 2011; Robledo et al., 2011). 
Cancer genes known to harbor genetic lesions in SMZL are 
not specific for this lymphoma type, and are limited to TP53, 
which is disrupted in 15% of cases, most likely as a secondary 
genetic alteration (Gruszka-Westwood et al., 2001; Salido et al., 
2010; Rinaldi et al., 2011), and to genes of the NF-kB path-
way, which are mutated in 30% of cases (Rossi et al., 2011; 
Yan et al., 2012). Scant knowledge of somatic gene lesions 
associated with SMZL limits the present understanding of its 
pathogenesis and hampers the possibility of diagnosis and 
classification based on genetics, one of the mainstay criteria 
adopted by the World Health Organization Classification of 
Tumours of Hematopoietic and Lymphoid Tissues for the 
diagnosis of B cell lymphoma (Swerdlow et al., 2008).
By integrating whole-exome sequencing and genome-wide 
high-density single nucleotide polymorphism (SNP) array data, 
this study identifies alterations of key regulators of MZ develop-
ment in 60% of SMZL patients, with NOTCH2 representing 
the most frequently mutated gene in this lymphoma type.
RESULTS
Identification of recurrent targets  
of genetic alterations in SMZL
To discover somatic, nonsilent mutations and copy number 
aberrations (CNAs) that are clonally represented in the SMZL 
coding genome, and presumably contributed to the initial 
expansion of the tumor clone, we performed massively parallel 
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Alterations of NOTCH2
A molecular feature of SMZL revealed by this study is the 
presence of recurrent lesions in genes encoding for compo-
nents of the NOTCH signaling pathway, a master regulator of 
normal MZ development (Kuroda et al., 2003; Saito et al., 2003; 
of cases. Overall, the genes that are recurrently mutated in 
SMZL point to the involvement of specific programs impli-
cated in normal MZ development (NOTCH, NF-kB, B cell 
receptor, and Toll-like receptor signaling), as well as in chro-
matin remodeling and transcriptional regulation.
Figure 1. SMZL coding genome complexity. (a) Number and type of nonsilent mutations identified in the 8 discovery genomes. (b) The pattern of 
nucleotide substitutions in the discovery genomes revealed a predominance of transitions over transversions (121:67, ratio of 1.8) and a preferential tar-
geting of G and C nucleotides (66.0% affecting G/C compared with 34.0% affecting A/T nucleotides). (c) Mutation frequency at specific dinucleotides (red 
bars). A significant bias toward alterations at 5-CpG-3 dinucleotides, which accounted for 15.4% of all missense and nonsense changes, was docu-
mented. The expected frequencies (gray bars) correspond to the dinucleotide sequence composition of the Consensus CDS. Asterisks denote statistically 
significant differences in overrepresented changes, as assessed by a Poisson distribution after correction for multiple hypotheses. (d) Fraction of sequenc-
ing reads reporting individual somatic nonsilent variants (gray circles) in the discovery genomes. The large majority of the nonsilent mutations (82.1%) 
were present in at least 20% of the reads. (e) Overall number and frequency of somatically acquired CNAs. Losses of whole chromosomal arms were not 
observed and are thus not reported in the figure. (f) Combined load of somatically acquired genetic lesions in the discovery genomes, including nonsilent 
mutations and CNAs.
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allele (Table S3). Western blot analysis of NOTCH2 expres-
sion consitently revealed the presence of an aberrant band 
of lower molecular weight, corresponding in size to the 
predicted truncated NOTCH2 protein, in all mutated cases 
studied (Fig. 4). Copy number gains of NOTCH2 were 
never observed in 110 SMZL cases analyzed by SNP array 
and/or FISH analysis.
In 3 patients for which multiple samples were available 
from different involved organs, the same NOTCH2 muta-
tion was detectable at all sites, namely peripheral blood, bone 
marrow, and spleen. This observation suggests that the muta-
tion had been acquired before dissemination of the lymphoma 
clone to multiple anatomical sites.
To verify the specificity of NOTCH2 mutations for SMZL, 
NOTCH2 was investigated across the clinico-pathological 
spectrum of mature B cell tumors (n = 399). NOTCH2 muta-
tions were consistently absent in nodal MZ lymphoma (0/18), 
chronic lymphocytic leukemia (0/100), mantle cell lymphoma 
(0/20), follicular lymphoma (0/20), hairy cell leukemia (0/20), 
and multiple myeloma (0/22), whereas they occurred sporad-
ically in extranodal MZ lymphoma (1/65, 1.5%) and, in 
accordance with a previous study (Lee et al., 2009), were 
restricted to 5/134 (3.7%) diffuse large B cell lymphomas 
(DLBCL; Fig. 3 B).
The clinical impact of NOTCH2 mutations on SMZL 
overall survival (OS) was assessed in 94 patients with available 
Moran et al., 2007; Santos et al., 2007; Pillai and Cariappa, 2009; 
Hampel et al., 2011). Targeted resequencing of NOTCH2, 
a gene required for MZ B cell differentiation (Saito et al., 
2003; Moran et al., 2007; Pillai and Cariappa, 2009;  Hampel 
et al., 2011), showed recurrent mutations in 25/117 (21.3%) 
SMZLs, including 2/8 (25.0%) discovery cases and 23/109 
(21.1%) cases from the screening/extension panels. These 
data establish NOTCH2 as the most frequently mutated gene 
in SMZL (Fig. 2).
NOTCH2 mutations were represented in all instances 
by truncating events (14 frameshift indels and 11 nonsense 
mutations), and clustered within a hotspot region in exon 
34, including a recurrent p.R2400* nonsense mutation in 
6/25 (24.0%) cases (Fig. 3 A, Tables S3, and Table S7). 
NOTCH2 mutations were consistently absent in the het-
erodimerization domain or in other portions of the gene 
that are targeted by inactivating mutations in different can-
cer types (Wang et al., 2011b). Based on their distribution, 
all mutations were predicted to cause impaired degrada-
tion of the NOTCH2 protein through the elimination or 
truncation of the C-terminal PEST domain (Fig. 3 A). 
Analysis of paired normal DNA confirmed the somatic 
origin of the mutations in all cases for which material was 
available (n = 13). NOTCH2 mutations were present in 
40% of the reads by transcriptome sequencing, indicat-
ing allelic balance in the expression of the WT and mutated 
Figure 2. Recurrently targeted pathways in SMZL. Percentage of SMZL cases harboring mutations in selected genes belonging to cellular pathways 
that are recurrently altered in SMZL. Numbers at the bottom indicate the actual number of mutated cases over the total samples analyzed. Asterisks  
denote genes that are also implicated in Toll-like receptor responses. BCR, B cell receptor.
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of SMZL versus other MZ-derived lymphomas and versus 
indolent B cell lymphoproliferative disorders clinically mim-
icking SMZL.
Alterations in other genes of the NOTCH pathway
In addition to NOTCH2, other genes involved in NOTCH 
signaling and known to be relevant for normal MZ differentia-
tion were affected by genomic lesions in SMZL, including 
NOTCH1, SPEN, and DTX1 (Fig. 2; Kuroda et al., 2003; Saito 
et al., 2003; Santos et al., 2007; Pillai and Cariappa, 2009).
NOTCH1, a paralogue of NOTCH2 implicated in 
several phases of lymphoid development, including terminal 
B cell differentiation into immunoglobulin-secreting cells 
(Santos et al., 2007; Yuan et al., 2010), was affected in 6/117 
(5.1%) SMZLs by a recurrent 2-bp deletion (p.P2515fs*4) 
that truncates the PEST domain, similar to NOTCH2  
lesions (Fig. 6 A and Table S7). This deletion also repre-
sents the most common NOTCH1 alteration in chronic 
lymphocytic leukemia and mantle cell lymphoma (Fabbri 
et al., 2011; Wang et al., 2011a; Kridel et al., 2012; 
follow up. Consistent with the indolent behavior of this lym-
phoma type, the 5-yr OS of the SMZL cohort was 78.1% 
(95% CI, 67.8–88.4%). At 5 yr, SMZL patients harboring 
NOTCH2 mutations were characterized by a significantly 
higher OS probability (93.3%; 95% CI, 80.0–100%) com-
pared with patients harboring a WT NOTCH2 (74.3%; 95% 
CI, 61.4–87.2%; P = 0.048; Fig. 5). Consistent with the 
improved OS, cases harboring NOTCH2 mutations displayed 
a longer progression-free survival (PFS) after first-line treat-
ment compared with NOTCH2 WT patients (5-yr PFS 
in NOTCH2 mutated patients, 83%; 95% CI, 65.4–100%; 
5-yr PFS in NOTCH2 WT patients, 44.1%; 95% CI, 28.9–
58.3%; P = 0.020). There were no differences in major 
adverse events between NOTCH2-mutated and unmutated 
patients, as documented by a similar treatment-related mor-
tality in the two groups (NOTCH2-mutated patients, 0/18; 
NOTCH2 WT patients 1/53, 1.8%; P = 1.000).
Overall, these data document that, among B cell neopla-
sia, NOTCH2-activating mutations are predominantly asso-
ciated with SMZL, and underscore the genetic individuality 
Figure 3. NOTCH2 is frequently mutated in SMZL. (a) Schematic representation of the human NOTCH2 gene (bottom) and protein (top), with its key 
functional domains (EGF, epithelial growth factor; LNR, LIN-12/NOTCH repeats; HD, heterodimerization; TM, transmembrane; RAM, regulation of amino 
acid metabolism; TAD, transactivation domain). Color-coded symbols indicate the type and position of the mutations. (b) Prevalence of NOTCH2 muta-
tions among mature B cell tumors (EMZL, extranodal MZ lymphoma; NMZL, nodal MZ lymphoma; HCL, hairy cell leukemia; CLL, chronic lymphocytic leu-
kemia; MCL, mantle cell lymphoma; FL, follicular lymphoma; MM, multiple myeloma). Numbers on the top indicate the actual number of mutated cases 
over the total samples analyzed.
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is implicated in the NOTCH signaling cascade (Kuroda 
et al., 2003; Li et al., 2005; VanderWielen et al., 2011). 
Consistent with its biochemical function, SPEN physiolog-
ically acts in the immune system as a negative regulator of 
B lymphocyte differentiation into MZ B cells by counter-
acting NOTCH activation (Kuroda et al., 2003). SPEN was 
found to be mutated in 6/117 (5.1%) SMZL cases (Fig. 2). 
With one exception, SPEN mutations were represented by 
inactivating events, including three frameshift indels and 
two nonsense substitutions (Fig. 6 A and Table S7), which 
were documented to be of somatic origin in all cases with 
available paired normal DNA. SPEN-mutated alleles were 
predicted to encode truncated proteins lacking the C-terminal 
domain involved in the interaction of SPEN with RBPJ, 
and to be necessary for NOTCH signaling inhibition 
(Fig. 6 A; Kuroda et al., 2003). In addition to truncating 
mutations, SPEN was affected by one somatic missense sub-
stitution, categorized as probably damaging by PolyPhen-2 
(Fig. 6 A and Table S7), and by four monoallelic deletions 
(Table S8). In all evaluable cases, SPEN mutations were re-
stricted to a single allele and were not accompanied by dele-
tions of the second allele. This pattern of predominant 
monoallelic inactivation is in agreement with in vitro models, 
suggesting that SPEN mutants may exert a dominant-negative 
effect (Li et al., 2005).
DTX1 encodes a RING finger ubiquitin ligase that 
binds the NOTCH family proteins and modulates their sig-
naling, is highly expressed in MZ B cells, and may be im-
portant for late steps of B cell differentiation (Izon et al., 
2002; Saito et al., 2003). In 2/117 (1.7%) SMZLs, DTX1 
was affected by somatically acquired missense substitutions 
mapping within two functionally relevant domains: the 
WWE1 domain, which mediates physical interactions be-
tween DTX1 and NOTCH (Zweifel et al., 2005), and the 
proline-rich domain, which may serve as a dock-
ing site for NOTCH inhibitory factors (Matsuno 
et al., 2002; Fig. 6 A; Tables S3 and S7).
In summary, 32% (37/117) of SMZL pa-
tients carry alterations of genes belonging to the 
NOTCH pathway, with NOTCH2 mutations 
accounting for approximately 2/3 of the events 
(25/37; 67.5%; Fig. 7).
Alteration of additional pathways involved  
in MZ development
Besides NOTCH signaling, the development of 
a normal MZ requires B cell migration to and 
retention within the spleen marginal sinus until 
they are activated (Pillai and Cariappa, 2009). 
SWAP70 encodes for an F-actin–binding/Rho 
GTPase–interacting protein that is necessary for 
Quesada et al., 2012; Rossi et al., 2012), and the most recur-
rent NOTCH1 PEST domain mutation in T cell acute lym-
phoblastic leukemia, where it causes impaired degradation 
of the NOTCH1 protein (Weng et al., 2004).
SPEN, also known as MINT, has been reported to re-
press NOTCH signaling by physically interacting with and 
causing inhibition of the transcription factor RBPJ, which 
Figure 4. NOTCH2 expression in SMZL. Western blot analysis of 
NOTCH2 protein expression in purified primary tumor cells from 5 SMZL 
cases carrying WT or mutated (M) NOTCH2, and in the SMZL cell line  
Karpas 1718, also WT for NOTCH2 (left); the specificity of the antibody 
was validated by using the BJAB cell line, which lacks NOTCH2 mRNA 
expression (right; asterisk indicates nonspecific band). Arrow indicates the 
intact NOTCH2 protein; a band of lower molecular weight, consistent with 
the predicted size of the NOTCH2 protein encoded by the mutant allele, 
can be detected in all NOTCH2-mutated patients, but not in NOTCH2 WT 
samples. Where available, the relative NOTCH2 mRNA levels in the same 
samples are quantified by qRT-PCR (bottom; na, not available).
Figure 5. NOTCH2 mutations are associated with  
better OS. Kaplan-Meier estimates of OS in SMZL patients 
(n = 94), according to NOTCH2 mutation status.
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(Fig. 6 A; Tables S3 and S7). SWAP70 was also affected by 
a monoallelic deletion in one additional SMZL (Table S4). 
Moreover, one SMZL (0.9%) displayed a somatic muta-
tion in the EGR1 B cell transcription factor, which also 
plays a role in MZ development (Table S3; Gururajan 
et al., 2008). EGR2, a paralogue of EGR1, was somatically 
mutated in one additional case (0.9%; Table S3).
Active NF-kB signaling is necessary for the generation 
and/or maintenance of normal MZ B cells (Calado et al., 2010; 
Chu et al., 2011; Conze et al., 2010; Pappu and Lin, 2006; 
Moran et al., 2007; Xie et al., 2007; Sasaki et al., 2008; Pillai and 
Cariappa, 2009). Mutations of both the canonical (17/117, 
14.5% cases) and noncanonical (11/117, 9.4% cases) NF-kB 
pathways were recurrent in SMZL (Fig. 2), and affected sev-
eral previously identified genes in this lymphoma type (Rossi 
et al., 2011; Yan et al., 2012), including IKBKB (8/117, 6.8%), 
TNFAIP3 (8/117, 6.8%), BIRC3 (6/117, 5.1%), TRAF3 
(4/117, 3.4%), and MAP3K14 (1/117, 0.9%; Fig. 6 B; Table S3 
and Table S7). These genes were also targeted by CNAs, in-
cluding deletions of TNFAIP3 (8/110, 7.2%), BIRC3 (7/110, 
6.3%), and TRAF3 (6/110, 5.4%), and gains of MAP3K14 
(7/110, 6.3%; Table S8).
In addition to genes specifically attributed to the NF-kB 
pathway, recurrent mutations were also found in CARD11 
and MYD88, which, among their many functions, act as 
positive regulators of NF-kB in signaling from the B cell 
receptor and Toll-like receptor, respectively (Fig. 2; Lenz 
et al., 2008; Ngo et al., 2011). CARD11 mutations (6 missense 
and 2 in frame deletions) cluster within the coiled-coil domain 
in 8/117 (6.8%) cases (Fig. 6 B and Table S7). In 6/117 
(5.1%) SMZLs, MYD88 was targeted by a recurrent missense 
substitution (p.L265P) that has been previously reported in 
activated B cell–type DLBCL (Fig. 6 B and Table S7; Ngo 
et al., 2011).
Cases harboring NF-kB pathway mutations and cases 
harboring NOTCH pathway mutations did not differ in 
terms of clinical and biological features at presentation, in-
cluding age, sex, performance status, levels of hemoglobin, 
LDH, -2-microglobulin and albumin, HCV infection, IGHV 
mutation status, usage of the IGHV1-2*04 allele, stereotyped 
VH CDR3, 7q31-q32 deletion, 3q gain, or TP53 disruption 
(P > 0.05 in all instances).
Overall, mutations of positive and negative NF-kB reg-
ulators accounted for 40/117 (34.1%) SMZL cases (Fig. 7), 
implicating activation of NF-kB as a major contributor to 
the pathogenesis of this disease.
Alteration of genes involved in chromatin remodeling  
and transcriptional regulation
Apart from genes implicated in MZ development, whole-
exome sequencing revealed a second set of genes recurrently 
mutated in SMZL and regulating chromatin remodeling 
(Fig. 2). The MLL2 histone methyltransferase controls gene 
transcription by modifying the lysine-4 position of histone 3 
and is recurrently mutated in FL and DLBCL (Morin et al., 
2011; Pasqualucci et al., 2011b). Inactivating mutations of 
normal B cell trafficking across spleen compartments (Chopin 
et al., 2010a, 2011). In 4/117 (3.4%) cases, SWAP70 was 
disrupted by truncating mutations that removed the C-terminal 
domain of the protein required for binding to F-actin 
Figure 6. Mutations of genes belonging to the NOTCH, migration/
adhesion, NF-B, and B cell receptor pathways in SMZL. Schematic 
diagram of the proteins targeted by mutations in SMZL, with their key 
functional domains (a, NOTCH pathway; b, NF-kB pathway). Symbols 
indicate the type of mutation.
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receptor co-repressors for co-activators (Fig. 8; Table S3 and 
Table S7; Oberoi et al., 2011). TBL1XR1 mutations were 
monoallelic in three cases, whereas one case harbored a dis-
rupting mutation coupled to a missense substitution (Table S7). 
MLL2 occurred in 6/40 (15.0%) SMZLs (Fig. 8; Tables S3 
and S7), leading to removal or truncation of the C-terminal 
SET domain required for its enzymatic activity. In addition, 
two SMZLs showed a p.P692T somatic missense substitu-
tion. ARID1A, a member of the SWI-SNF chromatin re-
modeling family that was reported as mutated in several solid 
tumors (Wiegand et al., 2010), was targeted by genetic 
lesions in 4/40 (10.0%) cases, including 2 point mutations 
and 2 deletions (Fig. 8; Tables S3, S7 and S8). EP300 and 
CREBBP are two highly related acetyltransferases that are 
also recurrently disrupted in B cell lymphoma (Pasqualucci 
et al., 2011a) and acute lymphoblastic leukemia (Mullighan 
et al., 2011). Somatic missense mutations of EP300 were found 
in 2/40 (5%) SMZL cases (Fig. 8 and Table S3), whereas one 
additional patient harbored a small deletion that juxtaposes 
in-frame the first 16 exons of CREBBP to the C-terminal 
portion of the ZNF434 gene, thus abrogating the CREBBP 
acetyltransferase domain, as confirmed by transcriptome 
sequencing analysis (not depicted). Somatic mutations of 
SIN3A, encoding for a core component of the SIN3–
HDAC1/2 histone deacetylase complex, occurred in 3/40 
(7.5%) SMZLs, and, in two cases, targeted regions that 
are required for the recruitment of histone modification 
complexes (Fig. 8; Tables S3 and S7; Grzenda et al., 2009). 
Other genes involved in chromatin remodeling and found 
to be somatically mutated in single SMZL cases are repre-
sented in Fig. 2.
Mutations were also detected in other transcriptional 
regulators. TBL1XR1, an intrinsic component of the SMRT-
N-CoR transcription co-repressor machinery that was re-
cently found to be recurrently disrupted in B cell tumors 
(Perissi et al., 2008), showed mutations in 4/40 (10.0%) 
SMZLs (Fig. 2). Mutations (two frameshift deletions and three 
somatically acquired missense substitutions) targeted the pro-
tein WD domains implicated in the exchange of nuclear 
Figure 7. Mutually exclusive involvement of genes implicated in MZ development. In the heatmap, rows correspond to genes and columns repre-
sent individual patients. Color coding is based on gene mutation status (white, WT; red, mutated). Asterisks denote genes that also modulate Toll-like 
receptor responses. BCR, B cell receptor.
Figure 8. Mutations of genes involved in chromatin remodeling 
and transcriptional regulation. Schematic diagram of the indicated 
proteins, with their key functional domains. Symbols indicate the  
type of mutation.
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Mutations of genes implicated in MZ development 
(NOTCH, NF-kB, B cell receptor, and Toll-like receptor 
pathway, as well as SWAP70, EGR1, EGR2; Izon et al., 
2002; Kuroda et al., 2003; Saito et al., 2003; Moran et al., 
2007; Santos et al., 2007; Gururajan et al., 2008; Pillai and 
Cariappa, 2009; Chopin et al., 2010b, 2011; Hampel et al., 
2011) show a largely mutually exclusive distribution pattern, 
although the number of cases (n = 117) lacks statistical power 
for this type of analysis (Fig. 7). Collectively, these lesions 
account for the majority of SMZL cases (70/117; 59.8%), and 
suggest that alterations in genes affecting B cell fate decision 
toward MZ differentiation represent alternative mechanisms 
converging on the deregulation of a common downstream 
target, which may include NF-kB.
DISCUSSION
One goal of this study was to provide initial information on 
the landscape of somatic genetic lesions (type and frequency) 
that characterize the SMZL coding genome. Given the pres-
ence of 25 nonsilent mutations and 5 CNAs per case (on 
average, 30 alterations/case), SMZL appears to show a de-
gree of genomic complexity that is intermediate between 
that of aggressive lymphoma, namely DLBCL (90 nonsilent 
mutations per case; Morin et al., 2011; Pasqualucci et al., 
2011b; Lohr et al., 2012), and that of previously untreated 
chronic lymphocytic leukemia (12 nonsilent mutations per 
case; Fabbri et al., 2011; Quesada et al., 2012), which shares 
an indolent course with SMZL.
A second key finding of this study was the identification 
of alterations in genes affecting B cell fate decision toward 
MZ differentiation as significantly associated with SMZL. Alter-
ations in genes of the NOTCH pathway emerged as highly 
recurrent (30%) in SMZL, with NOTCH2, a key regulator 
of MZ development, being the most frequently mutated gene 
(20%). All NOTCH2 mutations observed in SMZL cause 
disruption of the protein inhibitory PEST domain and are 
predicted to activate NOTCH2 signaling (Lee et al., 2009). 
Because of the lack of xenograft and cell line models of SMZL, 
we are currently unable to assess whether these mutations 
Three additional SMZLs showed monoallelic TBL1XR1  
deletion (Table S8). GPS2, another member of the SMRT-
N-CoR transcription co-repressor machinery that physically 
interacts with TBL1XR1 (Oberoi et al., 2011), was biallelically 
inactivated in one SMZL by a nonsense mutation with dele-
tion of the second allele (Table S3 and Table S4). The mutation 
targeted the GPS2 domain required for TBL1XR1 interaction. 
Monoallelic deletions of GPS2 were observed in additional 
eight cases (Table S8).
Overall, mutations of chromatin remodeling and tran-
scriptional regulation genes occurred in 14/40 (35.0%) 
SMZLs and, as observed in other cancer types (Gui et al., 
2011), were frequently concurrent in the same patient (50% 
of the mutations; Fig. 9), suggesting that they cooperate to 
promote tumorigenesis.
Mutations of genes regulating MZ development  
and NF-B activation characterize 60% of SMZLs
Given the biological heterogeneity of SMZLs, we investi-
gated the relationship between mutations of genes control-
ling MZ development and established genetic, immunogenetic, 
and biological subgroups of SMZLs, including those defined 
by deletion of 7q31-q32 (21/110, 19.1%), 3q gain (14/110, 
12.7%), expression of unmutated IGHV genes (29/110, 26.3%), 
usage of the IGHV1-2*04 allele (26/110, 23.6%), usage of 
stereotyped VH CDR3 (9/110, 8.1%), positive HCV serol-
ogy (11/86, 12.7%), and TP53 mutations (17/117, 14.5%). 
This analysis did not disclose any selective association, sug-
gesting that mutations of genes controlling MZ development 
play an independent role in lymphomagenesis (Table S9). 
A preferential, though not selective, association was observed 
between deletion of 7q31-q32, a cytogenetic abnormality 
characteristic of SMZL, and cases harboring mutations of MZ 
development genes (19/64, 29.7% in cases harboring muta-
tions vs. 2/46, 4.3% in cases devoid of mutations; P = 0.001; 
Table S9). In particular, deletion of 7q31-q32 significantly 
associated with SMZL harboring NOTCH2 mutations (11/24, 
45.8%; P = 0.001).
Figure 9. Integrated analysis of mutations affecting chromatin remodeling genes in SMZL. In the heatmaps, rows correspond to mutated genes 
and columns represent individual patients. Color coding is based on gene mutation status (white, WT; red, mutated). Analysis of chromatin remodeling 
genes was extended to the screening panel only (in total, 40 cases), and is thus shown separately.
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2010a, 2011). Thus, the finding that 60% of SMZL cases dis-
play the alternative deregulation of these pathways suggests that 
one major component of SMZL pathogenesis is the constitu-
tive activation of signals normally deputed to the differentiation 
and homing of B cells into the MZ.
Finally, the results herein have important implications for 
the clinical management of SMZL. Because the differential 
diagnosis of SMZL from other indolent B cell lymphoprolif-
erative disorders clinically mimicking SMZL is often com-
plex (Matutes et al., 2008; Swerdlow et al., 2008), some of 
the genetic alterations reported here, specifically mutations of 
NOTCH2, may serve as potentially helpful markers. More 
importantly, the results of this study provide a rationale for 
the design of novel therapeutic strategies for SMZL, which, 
to date, remains a disease orphan of specifically targeted drugs 
(Traverse-Glehen et al., 2011). New regimens may be useful 
to avoid splenectomy, a well-established therapeutic option 
in SMZL, which has perioperative and long-term morbid-
ity and mortality, especially in elderly or unfit individuals 
(Matutes et al., 2008).
The NOTCH pathway, which we show is affected by ge-
netic lesions in up to 30% of SMZLs, may represent an attrac-
tive candidate therapeutic target, as some NOTCH inhibitors, 
such as those preventing its enzymatic conversion to active 
transcription factor, are already available, and others are under 
active clinical development (Real et al., 2009). The NF-kB 
pathway represents an additional potential target; available 
proteasome inhibitors already approved for other malignan-
cies, or more specific anti–NF-kB compounds currently under 
development, should be tested for their efficacy in SMZL, 
either alone or in combination with NOTCH inhibitors.
MATERIALS AND METHODS
Patients and tumor biopsies. The study panel comprised a total of 117 
SMZL samples obtained from frozen spleen biopsies of newly diagnosed, 
previously untreated patients, and was distinguished into a discovery panel 
(n = 8 cases), a screening panel (n = 32 cases), and an extension panel (n = 77 
cases). Out of the 109 SMZLs used as screening and extension panel, 61 
were already reported (Rossi et al., 2011). In all cases, the SMZL diagnosis 
was based on spleen histology and was confirmed by centralized pathological 
revision (S.A. Pileri). Consistent with a SMZL diagnosis, all cases of the dis-
covery and screening panels lacked the t(11;18) and the t(14;18) transloca-
tions (Matutes et al., 2008), and all 117 cases lacked the BRAF p.V600E 
mutation (Swerdlow et al., 2008; Tiacci et al., 2012). Matched normal DNA 
was obtained from saliva or peripheral blood granulocytes in 48 patients 
(n = 8 discovery cases and 40 cases from the screening and extension panel). 
The clinical and biological characteristics of cases belonging to the SMZL 
discovery, screening, and extension panels are summarized in Tables S1, S5, 
and S6, respectively.
For comparative purposes, 399 B cell tumors other than SMZL were 
also included in the study (18 nodal MZ lymphomas, 65 extranodal MZ 
lymphomas, 100 chronic lymphocytic leukemias, 20 mantle cell lymphomas, 
20 follicular lymphomas, 134 DLBCLs, 20 BRAF p.V600E mutation-positive 
hairy cell leukemias, and 22 multiple myelomas). All of the 399 samples 
had been obtained at diagnosis from the involved site (lymph nodes or ex-
tranodal sites in the case of lymphoma; CD138+ cells purified from bone 
marrow aspirates in the case of multiple myeloma; peripheral blood purified 
B cells in the case of hairy cell leukemia; and peripheral blood mononuclear 
cells in the case of chronic lymphocytic leukemia). The number of mature 
confer ligand independence, or whether the mutated pro-
teins still require activation by ligand binding. Disruption 
of the PEST domain renders SMZL-associated mutations 
of NOTCH2 analogous to those involving NOTCH1 in 
chronic lymphocytic leukemia and mantle cell lymphoma, 
and to a subset of NOTCH1 mutations in T cell acute lym-
phoblastic leukemia (Fabbri et al., 2011; Wang et al., 2011a; 
Kridel et al., 2012; Quesada et al., 2012). Nevertheless, 
NOTCH2 mutations appear to be relatively specific for 
SMZL, being virtually absent in other major types of mature 
B cell neoplasia and rare in DLBCL (Lee et al., 2009). Con-
sistent with our findings, one single mutation of NOTCH2 
was recently described in one case of SMZL (Trøen et al., 
2008). In addition to NOTCH2, other modulators or mem-
bers of the NOTCH pathway were targeted by genetic 
lesions in SMZL, including SPEN, DTX1, and NOTCH1. 
The alternative involvement of multiple genes converging 
on the NOTCH pathway, together with the well-established 
functional role of some of these alterations, namely NOTCH1 
mutations in T cell acute lymphoblastic leukemia (Weng 
et al., 2004), strongly support their pathogenic role in SMZL.
As is the case for most cancer-associated genetic lesions, 
activation of NOTCH2 may not be sufficient for malignant 
transformation. In fact, patients affected by the Hajdu-Cheney 
syndrome, an autosomal-dominant genetic disease that causes 
severe and progressive bone loss and is associated with germ-
line NOTCH2 mutations analogous to those identified in 
SMZL, do not develop lymphomas (Brennan and Pauli, 2001; 
Simpson et al., 2011). Similarly, transgenic mice engineered 
to express activating NOTCH2 mutations in mature B cells 
display an expansion of the MZ at the expense of the follic-
ular compartment, but do not develop lymphoma (Hampel 
et al., 2011). It is important to note, however, that lymphoma 
development may require longer times than those observed 
so far both in Hajdu-Cheney patients (no diagnosed indi-
vidual was >50 yr old; Brennan and Pauli, 2001; Simpson 
et al., 2011) and in mice (1 yr), consistent with the elderly age 
and indolent course of SMZL (Hampel et al., 2011).
Collectively, the genetic alterations associated with SMZL 
appear to predominantly involve signaling pathways that regu-
late MZ development, including: (a) NOTCH, via the alterna-
tive mutation of multiple genes (NOTCH2, NOTCH1, SPEN, 
and DTX1); (b) NF-kB, via mutation of TNFAIP/A20, BIRC3, 
TRAF3 and CARD11; and (c) the B cell receptor, via muta-
tion of CARD11. Indeed, at least in mice, the commitment of 
mature B cells to the MZ compartment requires signaling from 
NOTCH2 (Kuroda et al., 2003; Saito et al., 2003; Moran et al., 
2007; Santos et al., 2007; Pillai and Cariappa, 2009; Hampel 
et al., 2011), as well as activation of the NF-kB transcription 
complex (Xie et al., 2007; Sasaki et al., 2008; Calado et al., 
2010; Conze et al., 2010; Chu et al., 2011) and possibly antigen 
stimulation through the B cell receptor and Toll-like receptor 
(Pappu and Lin, 2006). The alteration of genes implicated in the 
physical retention of MZ B cells within the spleen might also 
be important for SMZL pathogenesis, as suggested by the 
observation of recurrent mutations in SWAP70 (Chopin et al., 
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conventional Sanger-based resequencing of PCR products obtained from 
both tumor and paired normal HMW genomic DNA using primers specific 
for the exon encompassing the variant. The sequences surrounding the ge-
nomic locations of the candidate tumor-specific nonsilent mutations were 
obtained from the UCSC Human Genome database, and PCR primers were 
derived from previously published studies (Parsons et al., 2011) or custom-
designed using the Primer 3 online software (http://frodo.wi.mit.edu/
primer3/). Of the 218 predicted nonsilent variants, 202 (validation rate, 
92.6%) were confirmed to be somatic in origin by Sanger sequencing, 
6 were also found in the matched normal DNA, thus representing previously 
nonannotated germline polymorphisms that had not been detected by the 
high-throughput sequencing analysis, and the remaining 10 variants were 
absent in both tumor and normal genomic DNA, when tested by Sanger 
sequencing. Confirmed, somatic nonsynonymous mutations were tested for 
their functional consequences in silico by using the PolyPhen-2 (Polymor-
phism Phenotyping) algorithm (http://genetics.bwh.harvard.edu/pph2/), 
which is based on structure and sequence conservation. Genes found to 
be mutated were verified for their presence in the Catalogue of Somatic 
Mutations in Cancer database (Forbes et al., 2011) and in the Cancer Gene 
Census database.
Mutation screening of identified genes. The complete coding sequences 
and exon–intron junctions of selected genes identified through the whole-
exome sequencing and/or the SNP array approach were analyzed in the 
SMZL screening panel and extension panel by PCR amplification and direct 
sequencing of whole-genome–amplified DNA obtained using the Repli-g 
Mini kit (QIAGEN). Sequences for all annotated exons and flanking splice 
sites were retrieved from the UCSC Human Genome database using the 
corresponding mRNA accession number as a reference. PCR primers, 
located 50 bp upstream or downstream to target exon boundaries, were 
either derived from previously published studies (Parsons et al., 2011) or 
designed in the Primer 3 program and filtered using UCSC in silico PCR to 
exclude pairs yielding more than a single product. All PCR primers and 
conditions are available upon request. Purified amplicons were subjected to 
conventional DNA Sanger sequencing using the ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems), and compared with the corresponding germ-
line sequences using the Mutation Surveyor Version 3.97 software package 
(SoftGenetics) after automated and/or manual curation. Of the evaluated se-
quences, 99% had a Phred score of ≥20 and 96% had a score of ≥30. Candi-
date somatic mutations were confirmed from both strands on independent 
PCR products obtained from HMW genomic DNA. Synonymous muta-
tions, previously reported germline polymorphisms, and changes in the 
matched normal DNA (when available) were removed from the analysis. 
The following databases were used to exclude known germline variants 
in primary cases for which paired normal DNA was not available: Human 
dbSNP Database at NCBI (build 136), Ensembl Database, the 1000 Genomes 
Project, five single-genome projects available at the UCSC Genome Bio-
informatics resource.
High-density SNP array analysis. Copy number abnormalities were as-
sessed by high-density SNP array analysis in 81 of the 117 SMZL cases, in-
cluding the 8 discovery cases (paired tumor and normal DNA), 21 SMZL 
from the screening panel (both sets using the Genome-Wide Human SNP 
Array 6.0; Affymetrix), and 52 SMZL cases from the extension panel (using 
the GeneChip Human Mapping 250K NspI; Affymetrix; GEO accession 
no. GSE24881). In brief, HMW genomic DNA was restriction enzyme 
digested, ligated, PCR amplified, purified, labeled, fragmented, and hybrid-
ized to the arrays according to the manufacturer’s instructions. Identification of 
segments of abnormal copy numbers were performed using the dChipSNP 
software, and a karyotype-guided normalization procedure according to a 
published workflow (Pasqualucci et al., 2011b).
Whole-transcriptome sequencing (RNA-seq). Whole-transcriptome 
sequencing was performed in 6 SMZL cases belonging to the discovery 
panel (cases 12D through 17D). RNA was extracted from CD19+ B cells 
B cell neoplasms included in each panel was estimated to allow a 90% prob-
ability of identifying genes that are mutated in at least 10% of cases.
Patients provided informed consent in accordance with local IRB re-
quirements and The Declaration of Helsinki. The study was approved by the 
Ethical Committee of the Ospedale Maggiore della Carità di Novara affili-
ated with the Amedeo Avogadro University of Eastern Piedmont (Protocol 
Code 59/CE; Study Number CE 8/11) and by the Institutional Review 
Board of Columbia University.
DNA extraction. High molecular weight (HMW) genomic DNA was ex-
tracted from tumor and normal samples according to standard procedures 
(Rossi et al., 2011). In all tumor cases, the fraction of tumor cells in the tissue 
biopsy section used for molecular studies was estimated to be >70% by mor-
phology, immunohistochemistry, and/or flow cytometry. DNA was quanti-
fied by the Quant-iT PicoGreen reagent (Invitrogen) in the discovery panel, 
and by the NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific) 
in the screening and extension panels. All DNA samples were verified for 
integrity by 1% agarose gel electrophoresis. Tumor cell clonality was estab-
lished by amplification of the rearranged IGH genes, as described in detail 
in the paragraph “IGHV-IGHD-IGHJ rearrangement analysis.” Analysis of 
patient-specific IGHV-IGHD-IGHJ rearrangements were also performed in 
the paired normal DNA to exclude contamination from tumor cells.
Whole-exome capture and massively parallel sequencing. Purified 
tumor and germline genomic DNA (3 µg) from the 8 discovery SMZL cases 
was enriched in protein coding sequences using the in-solution exome cap-
ture SureSelect Human All Exon 50Mb kit (Agilent Technologies), accord-
ing to the manufacturer’s protocol. The SureSelect Human All Exon 50 Mb 
kit encompasses all coding exons annotated by the GENCODE project, 
including all exons in the Consensus CDS (CCDS, March 2009) database, 
10 bp of flanking sequence for each targeted region, and small noncoding 
RNAs from miRBase (v.13) and Rfam. The captured targets were subjected 
to massively parallel sequencing using the Illumina HiSeq 2000 analyzer 
(Illumina) with the paired-end 2 × 100 bp read option, following the manu-
facturer’s instructions. As quality controls for the precapture and post-capture 
steps, randomly selected PCR-amplified clones of the PCR products were 
subjected to Sanger sequencing to verify their preferential alignment to 
human genomic regions and to human coding transcripts (n = 50/library). 
Exome capture and massively parallel sequencing were performed at the 
HiSeq Service of Fasteris SA (Plan-les-Ouates, Switzerland).
Sequence mapping and identification of tumor-specific variants. 
Paired-end reads (102.5 million per case) obtained by high-throughput 
sequencing were aligned to the human genome reference hg19/NCBI 
GRCh37 using the BWA alignment tool version 0.5.9, and provided a mean 
depth of 111x with at least 83% of the target exome covered at 30x (Table S2). 
Sequence variants, i.e., differences from the reference sequence, were 
identified separately for each tumor and normal sample. The frequency of 
each variant was estimated from the total number of reads covering the posi-
tion of that variant. Using the SAVI (Statistical Algorithm for Variant Identi-
fication) algorithm developed at Columbia University (Tiacci et al., 2012), 
an empirical prior was constructed for the variant frequencies. From that 
prior, we obtained a corresponding high-credibility interval (posterior prob-
ability ≥1–105) for the frequency of each variant and a high-credibility in-
terval for the corresponding change in frequency between the tumor and the 
normal samples. 218 nonsilent variants, which are not reported in dbSNP 
135 and had high posterior probability (≥1–105) of nonzero presence in the 
tumor, as well as at least 1% change from the normal with high posterior 
probability (≥1-105), were kept for validation by Sanger sequencing. 
A comparison with data obtained by high-density SNP array analysis of the 
same tumor/normal pairs established the sensitivity of the method at 96.6% 
for heterozygous SNP calls and 98% for homozygous SNP calls.
Validation of candidate somatic mutations by DNA Sanger sequencing. 
Candidate nonsilent somatic mutations were subjected to validation by 
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reagent, and signals were visualized using a BX51 microscope (Olympus). 
The presence of copy number abnormalities was scored when the percentage 
of nuclei showing the abnormality was >10%.
Immunoblotting. B cells were purified from the spleen of 3 NOTCH2 
WT and 2 NOTCH2-mutated SMZL patients by positive selection, using an 
anti-CD19 PE antibody, followed by anti-PE microbeads (Miltenyi Biotec). 
Whole-cell extracts were obtained from CD19-purified SMZL cells or ex-
ponentially growing cell lines in RIPA Buffer (140 mM NaCl, 10 mM Tris-
HCl, pH 7.5, 0.5% sodium deoxycholate 10x, 0.1% sodium-dodecyl-sulfate + 
1% Triton-X 100), according to standard protocols, and proteins were 
quantified using the Bradford assay. Equivalent amounts of lysates were re-
solved on 6% SDS-PAGE in reducing conditions. The immunoblot analysis 
of NOTCH2 expression was performed using a specific anti-NOTCH2 
antibody (Bethyl Laboratories) following the manufacturer’s instructions. 
An anti–rabbit HRP-conjugated antibody (Santa Cruz Biotechnology) 
was used as a secondary reagent. ERK1/2 (BD) was used as loading con-
trol. Image acquisition was performed using the ImageQuant LAS4000 
software (GE Healthcare).
RNA extraction and quantitative real-time PCR (qRT-PCR). RNA 
was extracted using RNeasy Plus Mini kit (QIAGEN) and converted to cDNA 
using the High Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems). qRT-PCR was performed using the 7900 HT Fast Real Time PCR 
System (SDS2.3 software) using commercial primers (TaqMan Gene Expres-
sion Assays; Applied Biosystems). The comparative CT method was used to cal-
culate the expression relative to the endogenous control (Serra et al., 2011).
Statistical analysis. OS was measured from date of initial presentation to 
date of death (event) or last follow-up (censoring). PFS was measured from 
date of initial presentation to date of disease progression or death as a result 
of any cause, or last follow-up (censoring). Treatment-related mortality was 
defined as any deaths reported by investigators as probably/possibly related 
to SMZL treatment. Survival was analyzed by the Kaplan-Meier method and 
compared by the log-rank test. Categorical variables were compared by 
2 test and Fisher’s exact test when appropriate. Continuous variables were 
compared by the t test. All statistical tests were two-sided. Statistical signifi-
cance was defined as P value < 0.05. The analysis was performed with the 
Statistical Package for the Social Sciences software v.19.
Accession codes. The whole-exome sequencing and copy number data 
reported in this paper have been deposited in dbGaP under accession 
no. phs000502.v1.p1 (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/ 
study.cgi?study_id=phs000502.v1.p1).
Online supplemental material. Table S1 shows the features of the 8 
SMZL discovery cases analyzed by whole-exome sequencing. Table S2 re-
ports the results of Illumina sequencing after whole-exome capture. Table S3 
reports the validated somatic mutations identified by whole-exome sequenc-
ing in the SMZL discovery panel. Table S4 illustrates the segments (regions) 
of tumor-acquired copy number alterations identified in the SMZL discov-
ery panel. Table S5 and Table S6 list the patient’s features in the screening 
and extension panel, respectively, Table S7 shows the mutations identified in 
the screening and extension panels by targeted resequencing of candidate 
genes. Table S8 reports the copy number aberrations encompassing any 
of the 61 genes that were subjected to targeted resequencing. Table S9 
relates the genetic, immunogenetic and biological features of SMZL and 
the mutations of MZ development genes. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20120904/DC1.
We would like to thank Vladan Miljkovic and the Genomics Technologies Shared 
Resource of the Herbert Irving Comprehensive Cancer Center at Columbia 
University for hybridization of the Affymetrix SNP6.0 arrays; Laurent Farinelli and 
the Fasteris SA facility at Plan-les-Ouates, Geneva, Switzerland, for assistance with 
the whole-exome capture and sequencing procedure.
purified from spleen disaggregation using the Allprep DNA/RNA Mini kit 
(QIAGEN). Polyadenylated RNA was selected after DNaseI treatment and 
used as a template for double-stranded cDNA synthesis. The 190–210 bp 
fraction was then isolated and PCR amplified, and libraries were constructed 
using the Illumina Genome Analyzer paired-end library protocol according 
to manufacturer’s instructions. As quality controls for the precapture and 
postcapture steps, randomly selected PCR-amplified clones of the PCR 
products were subjected to Sanger sequencing to verify their preferential 
alignment to human genomic regions and to human coding transcripts 
(50 clones/library). Transcriptome sequencing was performed at the HiSeq 
Service of Fasteris SA (Plan-les-Ouates, Switzerland).
Whole-transcriptome data analysis. Reads (mean, 17 M per case) ob-
tained by high-throughput sequencing were aligned to a human transcrip-
tome reference (113 M), obtained by stitching together the exons belonging 
to the RefSeq transcripts as reported at the UCSC Genome Browser, using 
the BWA alignment tool version 0.5.9. Sequence variants, i.e., differences 
from the reference sequence, were identified separately for each sample, and 
credibility intervals for those frequencies, as well as for the change in fre-
quency from the corresponding whole-exome DNA sequencing, were ob-
tained as described in “Sequence mapping and identification of tumor-specific 
variants.” Expression for each RefSeq transcript was calculated using non-
clonal (reads that map to the same exact position are counted once) reads per 
kilobase of exon model per million mapped reads. For each transcript, we 
first filter out clonal reads mapping to the same position, and then calculate 
the mean nonclonal read depth per base and normalize by the total number 
of nonclonal reads mapped to the transcriptome.
IGHV-IGHD-IGHJ rearrangement analysis. PCR amplification of 
IGHV-IGHD-IGHJ rearrangements was performed on HMW genomic 
DNA using IGHV leader primers or consensus primers for the IGHV FR1, 
along with appropriate IGHJ genes, as previously described (Rossi et al., 
2011). PCR products were directly sequenced with the ABI PRISM Big-
Dye Terminator v1.1 Ready Reaction Cycle Sequencing kit using the ABI 
PRISM 3100 Genetic Analyzer (both from Applied Biosystems). Sequences 
were analyzed using the IMGT databases and the IMGT/V-QUEST tool 
(version 3.2.17; Centre National de la Recherche Scientifique, LIGM, Uni-
versité Montpellier 2, Montpellier, France). The following immunogenetic 
information were recorded for all IGHV-IGHD-IGHJ rearrangements: 
IGHV gene and allele usage; percentage of identity to the closest germline 
IGHV allele; VH CDR3 length and composition, including IGHD; and IGHJ 
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